

PTO/SR/08A (10-01)

Approved for use through 10/31/2002. OMD 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/609,207
				Filing Date	June 26, 2003
				First Named Inventor	Lada Rasochova
				Art Unit	1638
				Examiner Name	(not yet assigned)
				Attorney Docket Number	WARF-100XCD1
Sheet	1	of	4		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BB ↓	U1	US-5,853,716	12-29-1998	TATTERSALL <i>et al.</i>	
	U2	US-5,500,380	03-10-1996	AHLQUIST <i>et al.</i>	
	U3	US-5,418,153	05-23-1995	MORI <i>et al.</i>	
	U4	US-5,824,856	10-20-1998	MORI <i>et al.</i>	
	U5	US-5,851,757	12-22-1998	OLIVO <i>et al.</i>	
	U6	US-5,817,512	10-05-1998	MORROW <i>et al.</i>	
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1*
		Country Code ² - Number ³ - Kind Code ⁴ (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					

Examiner Signature	/Brendan Baggot/	Date Considered	06/22/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 001.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 10 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08U (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substituted for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/609,207
		Filing Date	June 26, 2003
		First Named Inventor	Lada Rasochova
		Group Art Unit	1638
		Examiner Name	(not yet assigned)
		Attorney Docket Number	WARF-100XCD1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cita No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BB	R1	VERCHOT <i>et al.</i> , <i>J. of Virology</i> (1995), 69(6): 3668-3674	
	R2	ALLISON <i>et al.</i> , <i>J. of Virology</i> (1988), 62(10): 3581-3588	
	R3	FONTES <i>et al.</i> , <i>The Plant Cell</i> (1994), 6: 405-418	
	R4	BERGLUND <i>et al.</i> , "Enhancing immune responses using suicidal DNA vaccines", <i>Nature Biotech.</i> (1998), 16: 582-585	
	R5	DE JONG and AHLQUIST, "A hybrid plant RNA virus made by transferring the noncapsid movement protein from a rod-shaped to an icosahedral virus is competent for systemic infection", <i>Proc. Natl. Acad. USA</i> (1992), 89: 6808-6812	
	R6	DINANT <i>et al.</i> , "Bromovirus RNA replication and transcription requires compatibility between the polymerase- and helicase-like viral RNA synthesis proteins", <i>J. Virol.</i> (1993), 67: 7181-7189	
	R7	DZIANOTT and BUJARSKI, "Derivation of an infectious viral RNA by autolytic cleavage of <i>in vitro</i> transcribed viral cDNAs", <i>Proc. Natl. Acad. Sci. USA</i> (1989), 86: 4823-4827	
	R8	EDWARDS, "Mapping of the seed transmission determinants of barley stripe mosaic virus", <i>MPMI</i> (1995), 8: 900-915	
	R9	FRENCH and AHLQUIST, "Characterization and engineering of sequences controlling <i>in vivo</i> synthesis of bromo mosaic virus RNA3", <i>J. Virol.</i> (1988), 62(7): 2411-2421	
	R10	HEMENWAY <i>et al.</i> , "Characterization of infectious transcripts from a potato virus X cDNA clone", <i>Virology</i> (1990), 175: 365-371	
	R11	ISHIKAWA <i>et al.</i> , "In Vivo DNA expression of functional bromo mosaic virus RNA Replicons in <i>Saccharomyces cerevisiae</i> ", <i>J. of Virology</i> (1997), 71(10): 7781-7790	
	R12	JACKSON and HUNTER, "Hordelivirus relationships and genome organization", <i>Annu. Rev. Phytopathol.</i> (1989), 27: 95-121	
	R13	JANDA <i>et al.</i> , "High efficiency T7 polymerase synthesis of infectious RNA from cloned bromo mosaic virus cDNA and effect of 5' extensions on transcript infectivity", <i>Virology</i> (1987), 158: 259-262	

Examiner Signature	/Brendan Baggot/	Date Considered	06/22/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, US Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substituted for form 1419B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/609,207
		Filing Date	June 26, 2003
		First Named Inventor	Lada Rasochova
		Group Art Unit	1638
		Examiner Name	(not yet assigned)
		Attorney Docket Number	WARF-100XCD1
Sheet	3	of	4

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T‡
BB	R14	KAIDO <i>et al.</i> , "Inhibition of bromo mosaic virus (BMV) amplification in protoplasts from transgenic tobacco plants expressing replicable BMV RNAs", <i>J. of Gen. Virol.</i> (1995), 76: 2827-2833	
	R15	ISI IKAWA <i>et al.</i> , "Yeast mutations in multiple complementation groups inhibit bromo mosaic virus RNA replication and transcription and perturb regulated expression of viral polymerase-like gene" <i>PNAS</i> (1997), 94: 13810-13815	
	R16	LEWANDOWSKI and DAWSON, "Deletion of internal sequences results in tobacco mosaic virus defective RNAs that accumulate to high levels without interfering with replication of the helper virus", <i>Virology</i> (1990), 251(2): 427-437	
	R17	RASOCHOVA and MILLER, "Satellite RNA of barley yellow dwarf-RPV virus reduces accumulation of RPV helper virus RNA and attenuates RPV symptoms on oats", <i>Molecular Plant-Microbe Interact</i> (1998), 9: 648-650	
	R18	SELLING <i>et al.</i> , "Genomic RNA of an insect virus directs synthesis of infectious virions in plants", <i>PNAS</i> (1990), 87: 434-438	
	R19	TIMPE and KUHNE, "In Vitro transcript of a full-length cDNA of a naturally deleted RNA2 of barley mild mosaic virus (BaMMV) replicate in BaMMV-infected plants", <i>J. of General Virology</i> (1995), 76: 2619-2623	
	R20	TÖFFER <i>et al.</i> , "A set of plant expression vectors for transcriptional and translational fusions", <i>Nucleic Acids Res.</i> (1987), 15: 5890	
	R21	VAN DER VOSSEN <i>et al.</i> , "The 5' terminal sequence of Alfalfa mosaic virus RNA 3 is dispensable for replication and contains a determinant for symptom formation", <i>Virology</i> (1986), 221: 271-280	
	R22	ZHOU and JACKSON, "Analysis of cis-acting elements for replication of barley stripe mosaic virus RNA", <i>Virology</i> (1996), 219: 150-160	
	R23	POLO and DUBENSKY, "DNA vaccines with a kick", <i>Nature Biotech.</i> (1998), 16: 517-518	
	R24	PRICE <i>et al.</i> , "Complete replication of an animal virus and maintenance of expression vectors derived from it in <i>Saccharomyces cerevisiae</i> ", <i>PNAS</i> (1996), 93: 9465-9470	
	R25	RASOCHOVA <i>et al.</i> , "The Satellite RNA of barley yellow dwarf virus-RPV is supported by boot western yellows virus in Dicotyledonous Protoplasts and Plants", <i>Virology</i> (1997), 231: 182-191	
✓	R26	SACHER <i>et al.</i> , "Hybrid bromo mosaic virus RNAs express and are packaged in tobacco mosaic virus coat protein <i>in vivo</i> ", <i>Virology</i> (1988), 167: 15-24	

Examiner Signature	/Brendan Baggot/	Date Considered	06/22/2006
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.

† Burden Hour Statement. This form is estimated to take 20 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/09B (10-01)

Approved for use through 10/31/2002 OMB 0051-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PFO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/609,027
		Filing Date	June 26, 2003
		First Named Inventor	Lada Rasochova
		Group Art Unit	1638
		Examiner Name	(not yet assigned)
		Attorney Docket Number	WARF-100XCD1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BB	R27	KASHIWAZAKI <i>et al.</i> , "Nucleotide sequence of barley yellow mosaic virus RNA1: a close evolutionary relationship with potyviruses", <i>J. of General Virology</i> (1990), 71: 2781-2790	
	R28	KASHIWAZAKI <i>et al.</i> , "Nucleotide sequence of barley yellow mosaic virus RNA2", <i>J. of General Virology</i> (1991), 72: 995-999	
	R29	KIKKERT, "The biolistic PDS 1000/He device", <i>Plant Cell Tiss. and Org. Cult.</i> (1993), 33: 221-226	
	R30	MORI <i>et al.</i> , "Infectivity of plasmids containing bromo mosaic virus cDNA linked to the cauliflower mosaic virus 35S RNA promoter", <i>J. of Gen. Virology</i> (1991), 72: 243-246	
	R31	MORI <i>et al.</i> , "Expression of bromo mosaic virus-coded replicase genes in transgenic tobacco plants", <i>J. of Gen. Virology</i> (1992), 73: 169-172	
	R32	NEELEMAN <i>et al.</i> , "Infection of tobacco with alfalfa mosaic virus cDNAs sheds light on the early function of the coat protein", <i>Virology</i> (1993), 196: 883-887	
	R33	PACHA and AHLQUIST, "Use of bromovirus RNA3 hybrids to study template specificity in viral RNA amplification", <i>J. of Virology</i> (1991), 65: 3693-3703	
	R34	PETTY and JACKSON, "Mutational analysis of barley stripe mosaic virus RNA beta", <i>Virology</i> (1990), 179: 712-718	
	R35	CROOKE, "Antisense Research and Application", <i>Basic Principles of Antisense Therapeutics</i> (1998), chapter 1	
	R36	BRANCH, "A good antisense molecule is hard to find", <i>TIBS</i> (1998), 45-50	
	R37	PALU <i>et al.</i> , "In pursuit of new developments for gene therapy of human diseases", <i>J. of Biotech.</i> (1999), 68: 1-13	
	R38		
	R39		

Examiner Signature	/Brendan Baggot/	Date Considered	06/22/2006
--------------------	------------------	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.